Gala Pharmaceuticals Inc. (GPI) will develop innovative tools for growing cannabis and marketing cannabis clone(s) products and will maximize clone yields.
GPI is developing:
1. Testing or Analytical Chemistry
High throughput screening technology for chemical composition and/or components. These components allow for the following:
2. GPI Genetic Fingerprinting
GPI Geno-breeding provides genetic “fingerprinting” of various cannabis strains. This fingerprinting allows for storing genetic fingerprint information into a proprietary database. GPI customers can access genetic fingerprint data which can be used for predictive breeding applications and for protecting intellectual property (IP).
3. Drug Formulations
The Company will provide cGMP (Good Manufacturing Practices) production of Active Pharmaceutical Ingredients (API) for use in clinical trials required to make effectiveness claims for varying medical conditions.
Gala Pharmaceuticals is executing two management contracts with iGot420 for the following: